HIVNCT06340698
Boosting the HRQoL Among HIV+ Mothers and Children
A study testing Resilience intervention and Adherence intervention in people with HIV and Perinatal HIV Infection, run by City University of Hong Kong at 1 site in China.
Trial summary
The goal of this randomized controlled trial is to test the effectiveness of a resilience intervention and an adherence intervention in improving health-related quality of life (HRQoL) among perinatally infected HIV positive children and their HIV positive mothers in China. The main questions it aims to answer are: 1. Read more about this study
- Who is it for?
- Ages 10 to 17 years
- Conditions the study is for
- HIV, Perinatal HIV Infection
- What is being tested?
- Resilience intervention and Adherence intervention
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 130 participants
- Where
- 1 siteChina
- Study dates
- 7 Jul 2024to 11 Jan 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 10 to 17 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- the child is HIV positive and perinatally infected, and receives HAART;
- the biological mother of the child is HIV positive and receives HAART;
- the mother is a primary caregiver of the child.
Who cannot join
- cannot complete the assessment due to a low education level or physical constraints;
- have been diagnosed with another life-threatening disease (e.g., cancer);
- have experienced a traumatic event (e.g., a severe car accident or bereavement) in the past 12 months.
Trial locations and contacts
1 site in 1 country.
China1 site
Guangxi Center for Disease Prevention and Control
Nanning, Guangxi, 530027
About this study
Official title: Joint Forces to Combat HIV: A Randomized Controlled Trial to Improve the Health-related Quality of Life (HRQoL) of HIV-positive Mothers and Children
The goal of this randomized controlled trial is to test the effectiveness of a resilience intervention and an adherence intervention in improving health-related quality of life (HRQoL) among perinatally infected HIV positive children and their HIV positive mothers in China.
The main questions it aims to answer are:
Read more
- Whether baseline resilience and treatment adherence are associated with the HRQoL;
- Whether the resilience intervention will improve the mediators associated with intervention sessions, such as positive coping and social support, the proximal outcome of resilience factors, the distal outcome of HRQoL, and dyadic level outcomes such as dyadic coping;
- Whether the adherence intervention will improve the mediators associated with intervention sessions, such as adherence information and behavioral skills, the proximal outcome of self-reported adherence, the distal outcome of HRQoL, and dyadic level outcomes such as dyadic coping;
- Whether the enhanced mediators (e.g., positive coping and social support) associated with the resilience-intervention sessions at the end of the intervention will transmit the effect of the resilience intervention on the increases in resilience factors during follow-ups;
- Whether the improved mediators (e.g., adherence information and behavioral skills) associated with the adherence-intervention sessions at the completion of the intervention will transmit the effect of the adherence intervention on the increases in adherence in follow-ups.
Participating mother-child dyads in the two intervention arms will receive two sessions of dyadic intervention. Researchers will compare the above-described outcomes between participants in the two intervention arms and the control arm (treatment as usual) to see the effectiveness of the interventions.
- Conditions
- HIV, Perinatal HIV Infection
- Being tested
- Resilience intervention, Adherence intervention
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Resilience interventionBehavioural
Contents of the first session include:
- Resilience. Know the concept of resilience.
- Stigma management. Discuss stigma experience and learn stigma management strategies such as normalizing the disease.
- Self-efficacy. Learn ways of improving self-efficacy, such as experience of success and social support.
Contents of the second session include:
- Mother-child interaction skills. Identify speaking styles that have a negative influence on mother-child interactions. Learn effective communication skills.
- Acquiring social support. Know people and resources that could provide support when having HIV-related difficulties and mental health problems.
- Emotional regulation. Understand the physiological responses to emotions. Know a range of emotional regulation strategies, such as cognitive reappraisal and deep breathing.
Adherence interventionBehavioural
Contents of the first session include:
- Adherence behavioral skills. Identify barriers to optimal HAART adherence. Know behavioral skills that can deal with these barriers, such as forgetting, afraid of others' questioning and side effects.
- Adherence information and motivation. Know how the HIV virus attack human body and the mechanisms of HAART medication. Understand the influence of adherence level on health outcomes.
Contents of the second session include:
- Adherence motivation. Discuss possibilities and hope of future life, intimate relationship and career.
- Mother-child interaction skills. Identify speaking styles that have a negative influence on mother-child interactions concerning HAART medication. Learn effective communication skills.
- Acquiring social support. Know people and resources that could provide support when having HAART-related difficulties and problems.
| Study group | Role | What they receive |
|---|---|---|
| Resilience intervention | Experimental | Participants (mother-child dyads) will receive two biweekly sessions of dyadic resilience intervention. Receives: Behavioral: Resilience intervention |
| Adherence intervention | Experimental | Participants (mother-child dyads) will receive two biweekly sessions of dyadic adherence intervention. Receives: Behavioral: Adherence intervention |
| Control | No intervention | Participants will receive usual medical treatment. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change of health-related quality of life (HRQoL)
HRQoL will be measured by the Chinese short version of the World Health Organization Quality of Life (Whoqol Group, 1998). Possible scores range from 0 (worst HRQoL) to 104 (Best HRQoL).
Measured: Baseline, 2 weeks (immediately after the last session of intervention), 1 month and 3 months
Change of depressive symptoms
Depressive symptoms will be measured by the Patient Health Questionnaire-9 (Kroenke, Spitzer, \& Williams, 2001). Possible scores range from 0 to 27, with a higher score indicating more depressive symptoms.
Measured: Baseline, 2 weeks (immediately after the last session of intervention), 1 month and 3 months
Change of anxiety symptoms
Anxiety symptoms will be measured by the Generalized Anxiety Disorder 7-item version (Spitzer et al., 2006). Possible scores range from 0 to 21, with a higher score indicating more anxiety symptoms.
Measured: Baseline, 2 weeks (immediately after the last session of intervention), 1 month and 3 months
Change of resilience factors
Resilience factors will be measured by the 25-item Connor-Davidson Resilience Scale (Connor \& Davidson, 2003). Possible scores range from 0 to 100, with a higher score indicating better resilience.
Measured: Baseline, 2 weeks (immediately after the last session of intervention), 1 month and 3 months
Change of HAART adherence
Adherence will be measured by (a) a visual analog scale asking the level of adherence (Zhang et al., 2020). Possible scores range from 0 (never adhere) to 10 (always adhere); and (b) single-item questions asking about missing and delayed doses in the last three days, seven days (one week) and 30 days (one month). Children will be asked to report their own adherence behaviors, and mothers will be asked to report both their own and their children's.
Measured: Baseline, 2 weeks (immediately after the last session of intervention), 1 month and 3 months
Change of mediators in the resilience intervention: Perceived stigma
Perceived stigma will be assessed by the 8-item HIV Stigma Scale (Berger et al., 2001; Li et al., 2016). Possible scores range from 8 to 32, with a higher score indicating a higher level of perceived stigma.
Measured: Baseline, 2 weeks (immediately after the last session of intervention)
Change of mediators in the resilience intervention: Emotional regulation
Emotional regulation will be assessed by the Emotional Management Strategy Questionnaire (Fabrizio et al., 2015). Possible scores range from 10 (worst emotional regulation) to 60 (best emotional regulation).
Measured: Baseline, 2 weeks (immediately after the last session of intervention)
Change of mediators in the resilience intervention: Positive coping
Positive coping will be assessed by a combination of the positive reappraisal subscale from the Cognitive Emotion Regulation Questionnaire (Garnefski et al., 2002; Zhu et al., 2008) and the Emotional Processing Subscale from the Emotional Approach Coping Scales (Stanon et al., 2000; Tse et al., 2020). Possible scores range from 8 to 40, with a higher score indicating better positive coping.
Measured: Baseline, 2 weeks (immediately after the last session of intervention)
Change of mediators in the resilience intervention: Social support
Social support will be assessed by a combination of the Perceived Social Support Scale (Blumenthal et al., 1987; Huang, Jiang, \& Ren, 1996), the possible scores of which range from 0 (lowest level of support) to 72 (highest level of support), and the usage of support subscale of the Social Support Assessment Scale (Xiao \& Yang, 1987), the possible scores of which range from 3 (lowest level of support utilization) to 12 (highest level of support utilization)
Measured: Baseline, 2 weeks (immediately after the last session of intervention)
Change of mediators in the resilience intervention: Self-efficacy
Self-efficacy will be assessed by the General Self-Efficacy Scale (Schwarzer \& Aristi, 1997). Possible scores range from 10 to 40, with a higher score indicating a higher level of efficacy.
Measured: Baseline, 2 weeks (immediately after the last session of intervention)
Change of mediators in the adherence intervention: Adherence information, motivation, and behavioral skills
Adherence information, motivation, and behavioral skills will be assessed by the LifeWindows Information-Motivation-Behavioral Skills Antiretroviral Therapy Adherence Questionnaire (LifeWindows Project Team, 2006; Peng et al., 2020). Possible scores of the information, motivation, and behavioral skills subscale range from 9 to 45, 8 to 40, and 13 to 65, respectively, with a higher score indicating a higher level of information, motivation, and behavioral skills.
Measured: Baseline, 2 weeks (immediately after the last session of intervention)
Change of mediators in the adherence intervention: Illness perception
Illness perception will be assessed by the Brief Illness Perception Questionnaire (Broadbent et al., 2006). Possible scores of each of the eight items range from 0 to 10, and each item will be used separately.
Measured: Baseline, 2 weeks (immediately after the last session of intervention)
Change of mediators in the adherence intervention: Adherence efficacy
Adherence efficacy will be assessed by the HIV Treatment Adherence Self-Efficacy Scale (Johnson et al., 2007; Sun et al., 2016). Possible scores range from 0 to 120, with a higher score indicating a higher level of perceived efficacy.
Measured: Baseline, 2 weeks (immediately after the last session of intervention)
Change of mediators in the adherence intervention: Children's medication-taking responsibility
Children's medication-taking responsibility perception and allocation (between mother and child) will be assessed by two visual analog scales respectively. Possible scores of each item range from 0 to 10, with a higher score indicating more self-responsibility than mother-responsibility.
Measured: Baseline, 2 weeks (immediately after the last session of intervention)
Secondary outcomes (5)
Change of mother-child relationship and interaction: Dyadic coping
Dyadic coping will be assessed by two subscales from the Dyadic Coping Inventory (Bodenmann, 2008), namely the common dyadic coping and the evaluation of the dyadic coping subscale. Possible scores range from 7 to 35, with a higher score indicating a higher level of dyadic coping.
Measured: Baseline, 2 weeks (immediately after the last session of intervention), 1 month and 3 months
Change of mother-child relationship and interaction: Mother-child closeness
Mother-child closeness will be assessed by the Closeness subscale of the Network of Relationships-Relationship Quality Version (Buhrmester \& Furman, 2008; Kong et al., 2012), the possible scores of which range from 15 (lowest level of closeness) to 90 (highest level of closeness) and the Inclusion of Other in the Self Scale (Aron, A., Aron, N., \& Smollan, 1992), the possible scores of which range from 1 (lowest level of closeness) to 7 (highest level of closeness).
Measured: Baseline, 2 weeks (immediately after the last session of intervention), 1 month and 3 months
Change of mother-child relationship and interaction: Family harmony
Family harmony will be assessed by the Family Harmony Scale (Kavikondala et al., 2016). Possible scores range from 10 to 60, with a higher score indicating a higher level of harmony.
Measured: Baseline, 2 weeks (immediately after the last session of intervention), 1 month and 3 months
Change of mother-child relationship and interaction: Mother-child conflict
Mother-child conflict will be measured by the frequency and intensity of parent-child conflicts (Yau \& Smetana, 1996), the possible scores of which range from 2 (no conflict) to 10 (highest level of conflict).
Measured: Baseline, 2 weeks (immediately after the last session of intervention), 1 month and 3 months
Change of mother-child relationship and interaction: Relationship satisfaction
Relationship satisfaction will be assessed by a single-item relationship ladder. Possible scores range from 0 to 10, with a higher score indicating a higher level of satisfaction.
Measured: Baseline, 2 weeks (immediately after the last session of intervention), 1 month and 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Apr 2024
- Study start7 Jul 2024
- Primary completion1 Sep 2025
- Study completion11 Jan 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HIVStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 130 participants (actual)
Sponsor and investigators
- Lead sponsor
- City University of Hong Kong
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dr. Nancy Xiaonan Yu, City University of Hong Kong
- Investigators
- Xiaonan N. Yu, Dr., Principal investigator, City University of Hong Kong
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06340698
- Sponsor's protocol ID
- GRF-11606221
- Status last verified
- Feb 2026
- First submitted
- 24 Mar 2024
- Last updated
- 25 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Joint Forces to Combat HIV: A Randomized Controlled Trial to Improve the Health-related Quality of Life (HRQoL) of HIV-positive Mothers and Children
- ClinicalTrials.gov ID
- NCT06340698
- Acronym / sponsor ID
- GRF-11606221
- Conditions
- HIV, Perinatal HIV Infection
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 130 participants (actual)
- Lead sponsor
- City University of Hong KongUniversity, hospital or other
- Study start
- 7 Jul 2024 (actual)
- Primary completion
- 1 Sep 2025 (actual)
- Study completion
- 11 Jan 2026 (actual)
- First posted
- 1 Apr 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this randomized controlled trial is to test the effectiveness of a resilience intervention and an adherence intervention in improving health-related quality of life (HRQoL) among perinatally infected HIV positive children and their HIV positive mothers in China.
The main questions it aims to answer are:
- Whether baseline resilience and treatment adherence are associated with the HRQoL;
- Whether the resilience intervention will improve the mediators associated with intervention sessions, such as positive coping and social support, the proximal outcome of resilience factors, the distal outcome of HRQoL, and dyadic level outcomes such as dyadic coping;
- Whether the adherence intervention will improve the mediators associated with intervention sessions, such as adherence information and behavioral skills, the proximal outcome of self-reported adherence, the distal outcome of HRQoL, and dyadic level outcomes such as dyadic coping;
- Whether the enhanced mediators (e.g., positive coping and social support) associated with the resilience-intervention sessions at the end of the intervention will transmit the effect of the resilience intervention on the increases in resilience factors during follow-ups;
- Whether the improved mediators (e.g., adherence information and behavioral skills) associated with the adherence-intervention sessions at the completion of the intervention will transmit the effect of the adherence intervention on the increases in adherence in follow-ups.
Participating mother-child dyads in the two intervention arms will receive two sessions of dyadic intervention. Researchers will compare the above-described outcomes between participants in the two intervention arms and the control arm (treatment as usual) to see the effectiveness of the interventions.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Resilience intervention | Experimental | Behavioral: Resilience interventionParticipants (mother-child dyads) will receive two biweekly sessions of dyadic resilience intervention. |
| Adherence intervention | Experimental | Behavioral: Adherence interventionParticipants (mother-child dyads) will receive two biweekly sessions of dyadic adherence intervention. |
| Control | No intervention | –Participants will receive usual medical treatment. |
Who may qualify
- Ages
- 10 to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (3 listed)
- the child is HIV positive and perinatally infected, and receives HAART;
- the biological mother of the child is HIV positive and receives HAART;
- the mother is a primary caregiver of the child.
Key exclusion criteria (3 listed)
- cannot complete the assessment due to a low education level or physical constraints;
- have been diagnosed with another life-threatening disease (e.g., cancer);
- have experienced a traumatic event (e.g., a severe car accident or bereavement) in the past 12 months.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Resilience interventionContents of the first session include: 1. Resilience. Know the concept of resilience. 2. Stigma management. Discuss stigma experience and learn stigma management strategies such as normalizing the disease. 3. Self-efficacy. Learn ways of improving self-efficacy, such as experience of success and social support. Contents of the second session include: 1. Mother-child interaction skills. Identify speaking styles that have a negative influence on mother-child interactions. Learn effective communication skills. 2. Acquiring social support. Know people and resources that could provide support when having HIV-related difficulties and mental health problems. 3. Emotional regulation. Understand the physiological responses to emotions. Know a range of emotional regulation strategies, such as cognitive reappraisal and deep breathing. | Behavioural | Resilience intervention |
| Adherence interventionContents of the first session include: 1. Adherence behavioral skills. Identify barriers to optimal HAART adherence. Know behavioral skills that can deal with these barriers, such as forgetting, afraid of others' questioning and side effects. 2. Adherence information and motivation. Know how the HIV virus attack human body and the mechanisms of HAART medication. Understand the influence of adherence level on health outcomes. Contents of the second session include: 1. Adherence motivation. Discuss possibilities and hope of future life, intimate relationship and career. 2. Mother-child interaction skills. Identify speaking styles that have a negative influence on mother-child interactions concerning HAART medication. Learn effective communication skills. 3. Acquiring social support. Know people and resources that could provide support when having HAART-related difficulties and problems. | Behavioural | Adherence intervention |
Primary outcome
Change of health-related quality of life (HRQoL)
Time frame: Baseline, 2 weeks (immediately after the last session of intervention), 1 month and 3 months
HRQoL will be measured by the Chinese short version of the World Health Organization Quality of Life (Whoqol Group, 1998). Possible scores range from 0 (worst HRQoL) to 104 (Best HRQoL).
Change of depressive symptoms
Time frame: Baseline, 2 weeks (immediately after the last session of intervention), 1 month and 3 months
Depressive symptoms will be measured by the Patient Health Questionnaire-9 (Kroenke, Spitzer, \& Williams, 2001). Possible scores range from 0 to 27, with a higher score indicating more depressive symptoms.
Change of anxiety symptoms
Time frame: Baseline, 2 weeks (immediately after the last session of intervention), 1 month and 3 months
Anxiety symptoms will be measured by the Generalized Anxiety Disorder 7-item version (Spitzer et al., 2006). Possible scores range from 0 to 21, with a higher score indicating more anxiety symptoms.
Change of resilience factors
Time frame: Baseline, 2 weeks (immediately after the last session of intervention), 1 month and 3 months
Resilience factors will be measured by the 25-item Connor-Davidson Resilience Scale (Connor \& Davidson, 2003). Possible scores range from 0 to 100, with a higher score indicating better resilience.
Change of HAART adherence
Time frame: Baseline, 2 weeks (immediately after the last session of intervention), 1 month and 3 months
Adherence will be measured by (a) a visual analog scale asking the level of adherence (Zhang et al., 2020). Possible scores range from 0 (never adhere) to 10 (always adhere); and (b) single-item questions asking about missing and delayed doses in the last three days, seven days (one week) and 30 days (one month). Children will be asked to report their own adherence behaviors, and mothers will be asked to report both their own and their children's.
Change of mediators in the resilience intervention: Perceived stigma
Time frame: Baseline, 2 weeks (immediately after the last session of intervention)
Perceived stigma will be assessed by the 8-item HIV Stigma Scale (Berger et al., 2001; Li et al., 2016). Possible scores range from 8 to 32, with a higher score indicating a higher level of perceived stigma.
Change of mediators in the resilience intervention: Emotional regulation
Time frame: Baseline, 2 weeks (immediately after the last session of intervention)
Emotional regulation will be assessed by the Emotional Management Strategy Questionnaire (Fabrizio et al., 2015). Possible scores range from 10 (worst emotional regulation) to 60 (best emotional regulation).
Change of mediators in the resilience intervention: Positive coping
Time frame: Baseline, 2 weeks (immediately after the last session of intervention)
Positive coping will be assessed by a combination of the positive reappraisal subscale from the Cognitive Emotion Regulation Questionnaire (Garnefski et al., 2002; Zhu et al., 2008) and the Emotional Processing Subscale from the Emotional Approach Coping Scales (Stanon et al., 2000; Tse et al., 2020). Possible scores range from 8 to 40, with a higher score indicating better positive coping.
Change of mediators in the resilience intervention: Social support
Time frame: Baseline, 2 weeks (immediately after the last session of intervention)
Social support will be assessed by a combination of the Perceived Social Support Scale (Blumenthal et al., 1987; Huang, Jiang, \& Ren, 1996), the possible scores of which range from 0 (lowest level of support) to 72 (highest level of support), and the usage of support subscale of the Social Support Assessment Scale (Xiao \& Yang, 1987), the possible scores of which range from 3 (lowest level of support utilization) to 12 (highest level of support utilization)
Change of mediators in the resilience intervention: Self-efficacy
Time frame: Baseline, 2 weeks (immediately after the last session of intervention)
Self-efficacy will be assessed by the General Self-Efficacy Scale (Schwarzer \& Aristi, 1997). Possible scores range from 10 to 40, with a higher score indicating a higher level of efficacy.
Change of mediators in the adherence intervention: Adherence information, motivation, and behavioral skills
Time frame: Baseline, 2 weeks (immediately after the last session of intervention)
Adherence information, motivation, and behavioral skills will be assessed by the LifeWindows Information-Motivation-Behavioral Skills Antiretroviral Therapy Adherence Questionnaire (LifeWindows Project Team, 2006; Peng et al., 2020). Possible scores of the information, motivation, and behavioral skills subscale range from 9 to 45, 8 to 40, and 13 to 65, respectively, with a higher score indicating a higher level of information, motivation, and behavioral skills.
Change of mediators in the adherence intervention: Illness perception
Time frame: Baseline, 2 weeks (immediately after the last session of intervention)
Illness perception will be assessed by the Brief Illness Perception Questionnaire (Broadbent et al., 2006). Possible scores of each of the eight items range from 0 to 10, and each item will be used separately.
Change of mediators in the adherence intervention: Adherence efficacy
Time frame: Baseline, 2 weeks (immediately after the last session of intervention)
Adherence efficacy will be assessed by the HIV Treatment Adherence Self-Efficacy Scale (Johnson et al., 2007; Sun et al., 2016). Possible scores range from 0 to 120, with a higher score indicating a higher level of perceived efficacy.
Change of mediators in the adherence intervention: Children's medication-taking responsibility
Time frame: Baseline, 2 weeks (immediately after the last session of intervention)
Children's medication-taking responsibility perception and allocation (between mother and child) will be assessed by two visual analog scales respectively. Possible scores of each item range from 0 to 10, with a higher score indicating more self-responsibility than mother-responsibility.
5 secondary outcomes
Change of mother-child relationship and interaction: Dyadic coping
Time frame: Baseline, 2 weeks (immediately after the last session of intervention), 1 month and 3 months
Change of mother-child relationship and interaction: Mother-child closeness
Time frame: Baseline, 2 weeks (immediately after the last session of intervention), 1 month and 3 months
Change of mother-child relationship and interaction: Family harmony
Time frame: Baseline, 2 weeks (immediately after the last session of intervention), 1 month and 3 months
Change of mother-child relationship and interaction: Mother-child conflict
Time frame: Baseline, 2 weeks (immediately after the last session of intervention), 1 month and 3 months
Change of mother-child relationship and interaction: Relationship satisfaction
Time frame: Baseline, 2 weeks (immediately after the last session of intervention), 1 month and 3 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Feb 2026.
- Individual participant dataSharing planned: No
Related trials for HIV
Not yet recruiting
HealthMpowerment Korea: Pilot Testing the Cultural Adaptation of a Digital HIV Intervention for Men Who Have Sex With Men in South Korea
HIV Infections, HIV Prevention and Care
Not yet recruiting
Prescribe to Prevent HIV: A Hybrid Trial Helping Addiction Clinics Prevent HIV & Infections Through Safer Drug Use Support
People Who Use Opioids/People With Opioid Use Disorder (OUD)
Recruiting
Evaluating the Impact of Using the B-OK Bottles for HIV and ART Literacy in South Africa
HIV, HIV Treatment
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
RecruitingObservational study
Olfactory Function and Model-Based Behavior in People Living With HIV and SUD
HIV, Substance Use Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Xiaonan N. Yu, Dr. principal investigator
City University of Hong Kong
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Resilience intervention and Adherence intervention in people with HIV and Perinatal HIV Infection, run by City University of Hong Kong at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 25 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change of health-related quality of life (HRQoL) (time frame: Baseline, 2 weeks (immediately after the last session of intervention), 1 month and 3 months). The study lists 14 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Feb 2026.